Immunogen initiated with "buy"

10/08/09 - Brean Murray, Carret & Co

NEW YORK, October 8 (newratings.com) - Analysts at Brean Murray initiate coverage of Immunogen (IMGN) with a "buy" rating. The target price is set to $14.